Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Northland Capital Markets Downgrades Adamas Pharmaceuticals to Market Perform, Announces $8.5 Price Target

Author: Benzinga Newsdesk | November 17, 2021 07:41am
Northland Capital Markets analyst Carl Byrnes downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) from Outperform to Market Perform and announces $8.5 price target.

Posted In: ADMS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist